Ipsen to cut primary care sales force as French reforms bite
This article was originally published in Scrip
Executive Summary
French pharmaceutical company Ipsen says it will likely lay off around 100 of its primary care sales team in France during the first half of next year following a strong decline in sales of its primary care products and a failure to find a partner for the business. The downturn is a consequence of continued measures being untaken by the country's new socialist government as it attempts to balance its healthcare books.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.